Archives
-
BRCA2, PARP Inhibition, and RAD51 Filament Protection
2026-09-12
The reference study identifies PARP1 retention on resected DNA as a direct source of RAD51 filament instability during PARP inhibition. Using biochemical reconstitution, single-molecule FRET, strand-exchange assays, and cellular localization microscopy, it shows that full-length BRCA2 protects homologous-recombination repair sites by preventing PARP1 accumulation on DNA.
-
Clathrin-Mediated Entry of Grass Carp Reovirus
2026-09-12
Wang et al. used complementary pharmacological, ultrastructural, and quantitative PCR approaches to show that genotype III grass carp reovirus GCRV104 enters CIK cells through a dynamin-dependent, clathrin-mediated pathway that requires endosomal acidification. The study also demonstrates why amiloride-sensitive uptake should not be assumed in every viral entry model: Amiloride did not inhibit GCRV104 or GCRV-JX01 entry under the tested conditions.
-
RIPA Lysis Buffer Strong: 5 Lab Scenarios
2026-09-11
This scenario-based guide explains how RIPA Lysis Buffer (Strong, without inhibitors), SKU K1120, can support protein recovery after cell viability, proliferation, and cytotoxicity assays. It covers compatibility, inhibitor selection, protocol parameters, data interpretation, and practical vendor comparison for Western blotting, immunoprecipitation, ELISA, and kinase workflows.
-
Sulfaphenazole Optimization for Safer Anti-TB Leads
2026-09-11
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP2C9 inhibition, identifying compound 10d as a particularly balanced lead. The study combines focused structural variation, synthesis, and parallel biological profiling to illustrate how liability-aware SAR can inform early anti-tuberculosis discovery.
-
5-(N,N-dimethyl)-Amiloride in Translational Research
2026-09-10
A mechanistic and strategic guide to using 5-(N,N-dimethyl)-Amiloride hydrochloride to connect Na+/H+ exchanger biology with intracellular pH regulation, endothelial injury, and cardiac ischemia-reperfusion research—while clearly separating established evidence from testable translational hypotheses.
-
NEDD4L–PRMT5 Axis in Colorectal Liver Metastasis
2026-09-10
The reference study identifies NEDD4L as an E3 ubiquitin ligase that suppresses colorectal cancer liver metastasis by binding and degrading PRMT5. Its integrated screening and mechanistic strategy connects PRMT5 turnover with AKT1 methylation and AKT/mTOR signaling, providing a useful framework for validating metastasis-associated protein interactions.
-
CF10–EdU Synergy Causes Telomere Attrition
2026-09-09
Das, Behl, and Gmeiner identify a distinct combination mechanism in which the fluoropyrimidine polymer CF10 enhances EdU incorporation into colorectal cancer cell DNA, producing double-strand breaks, telomere attrition, and mitotic catastrophe. The study provides a framework for interpreting fluoropyrimidine combinations through integrated DNA-damage, cell-cycle, telomere, and mitotic endpoints rather than viability measurements alone.
-
BMN 673 (Talazoparib) Inhibitor Lab Guide
2026-09-09
A practical, evidence-led guide to using BMN 673 (Talazoparib) in cell viability, proliferation, and cytotoxicity workflows. It explains how SKU A4153 supports DNA repair deficiency targeting through documented potency, PARP-DNA complex trapping, solvent compatibility, and storage guidance.
-
RAB31 and ESCRT-Independent Exosome Biogenesis
2026-09-08
The reference study identifies RAB31 as a coordinator of an ESCRT-independent exosome route that sorts EGFR into intraluminal vesicles through flotillin-rich membrane domains. It also shows that RAB31 limits multivesicular endosome degradation by recruiting TBC1D2B to suppress RAB7 activity, providing a mechanistic link between vesicle formation and exosome release.
-
Rucaparib (AG-014699, PF-01367338) Workflow Guide
2026-09-07
This scenario-based guide explains how Rucaparib (AG-014699, PF-01367338), SKU A4156, can support reproducible DNA damage response research and cell-based viability workflows. It covers mechanism, solvent compatibility, protocol setup, interpretation, transporter effects, and practical product-selection criteria.
-
Demethyleneberberine: From Mechanism to Translation
2026-09-07
Demethyleneberberine is a multi-pathway natural alkaloid with translational potential across inflammatory, autoimmune hepatitis, neuroprotective, and non-small cell lung cancer research. This evidence-led guide connects mechanism, model selection, assay design, compound handling, and strategic validation.
-
4-Phenylbutyric Acid: ER Stress Workflow
2026-09-05
Build clearer ER stress experiments with 4-Phenylbutyric acid, a chemical chaperone that helps test whether misfolded-protein stress drives apoptosis or autophagic cell death. This practical workflow translates liver-cancer findings into controlled rescue assays, with solvent, timing, readout, and troubleshooting guidance.
-
ATRA and Niraparib in Cisplatin-Treated Ovarian Cancer
2026-09-05
The reference study shows that all-trans retinoic acid can reduce cisplatin-associated resistance to PARP inhibition in epithelial ovarian cancer models. Its key contribution is a sequential treatment strategy linking ATRA activity to suppression of PARPi-resistance genes and intracellular NAD+ metabolism, with implications for maintenance therapy research.
-
Rucaparib and the Spliceosome–PARP Frontier
2026-09-04
The emerging link between SmD2 acetylation, BRCA1/FANC splicing, and PARP inhibitor response reframes Rucaparib research around biomarker-defined DNA repair states. This translational guide connects hepatocellular carcinoma findings with prostate cancer radiosensitization while distinguishing established evidence from testable hypotheses.
-
Targeted EPO mRNA Nanoparticles in SCI Repair
2026-09-04
The reference study develops mannose-modified lipid nanoparticles that target CD206-enriched inflammatory macrophages and microglia after spinal cord injury. By delivering EPO mRNA locally, the platform reduces neuroinflammation and ferroptosis while improving tissue preservation and motor recovery in mice, although its translational maturity remains preclinical.